Overview
IKT market data
Price History
IKT price chart
Valuation & Profitability
No Valuation Data Yet
Alpha Vantage and Twelve Data both returned no valuation metrics for IKT. Check back after the next daily valuation refresh — this symbol may be new, delisted, or temporarily unavailable from both providers.
Company news
8-K filing — Inhibikase Therapeutics, Inc. (IKT)SEC EDGAR · Jul 23, 2026, 12:32 PM
Inhibikase Therapeutics Says FDA Grants Orphan Drug Designation To Its Lead Product Candidate IKT-001, Prodrug Of Imatinib Mesylate, For Treatment Of PAHBenzinga · Jul 23, 2026, 12:03 PM
Danaher Posts Q2 Results, Joins Calix, Equifax And Other Big Stocks Moving Lower In Tuesday’s Pre-Market SessionBenzinga · Jul 21, 2026, 12:01 PM
Inhibikase Therapeutics shares are trading higher after the company announced that it has sold 25,000,000 shares of the company’s common stock to RA Capital Management through its at-the-market facility for gross proceeds of $50 million.Benzinga · Jul 14, 2026, 3:01 PM
Inhibikase Therapeutics Sells 25M Common Shares To RA Capital Management Through At-The-Market Facility For Gross Proceeds Of $50MBenzinga · Jul 14, 2026, 12:06 PM
Oppenheimer Initiates Coverage On Inhibikase Therapeutics with Outperform Rating, Announces Price Target of $5Benzinga · Jun 10, 2026, 6:05 PM
Pulmonary Arterial Hypertension Clinical Trial Pipeline Gains Momentum: 50+ Companies Lead the Charge in Pioneering New Treatments | DelveInsightGlobenewswire Inc · May 19, 2026, 5:15 PM
Inhibikase Therapeutics Q1 EPS $(0.10) Beats $(0.13) EstimateBenzinga · May 12, 2026, 8:40 PM